Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
Argus Health
Mallinckrodt
Deloitte
Federal Trade Commission
Farmers Insurance
Colorcon
Chinese Patent Office

Generated: February 19, 2019

DrugPatentWatch Database Preview

Litigation Details for Reliant Pharmaceuticals Inc. v. Par Pharmaceuticals Inc. (D. Del. 2006)

« Back to Dashboard

Reliant Pharmaceuticals Inc. v. Par Pharmaceuticals Inc. (D. Del. 2006)

Docket ➤ Sign Up Date Filed 2006-12-19
Court District Court, D. Delaware Date Terminated 2009-04-17
Cause 35:271 Patent Infringement Assigned To Joseph James Farnan Jr.
Jury Demand Defendant Referred To
Parties PAR PHARMACEUTICALS INC.; RELIANT PHARMACEUTICALS INC.
Patents 4,389,393; 5,446,070; 5,681,588
Attorneys Gerald J. Flattmann , Jr.; Jack B. Blumenfeld; James K. Stronski; John G. Taylor; Josy W. Ingersoll
Link to Docket External link to docket
Small Molecule Drugs cited in Reliant Pharmaceuticals Inc. v. Par Pharmaceuticals Inc.
The small molecule drugs covered by the patents cited in this case are ➤ Sign Up , ➤ Sign Up , and ➤ Sign Up .

Details for Reliant Pharmaceuticals Inc. v. Par Pharmaceuticals Inc. (D. Del. 2006)

Date Filed Document No. Description Snippet Link To Document
2007-02-09 11 Answer to Amended Complaint Reliant is the patent holder by assignment of U.S. Patent No. 5,681,588 (“the ’588 patent”). 8, Par submitted…infringed, or Will infringe U.S. Patent No. 5,681,588 (“the ’588 patent”). DBOZ:5777385.1 066039.1001 …, Par admits only (a) that U.S. Patent No. 5,681,588 (“the ’588 patent”) is entitled “Delayed Release …the ’588 patent. 15. The prior art in question, U.S. Patent No. 4,797,287 (“the ’287 patent”), reads …prosecution of the ’588 patent, knew about the ’287 patent at the time that the ’588 patent was filed.' Court External link to document
2007-09-21 114 Order against defendant Par. The patent-in-suit, U.S, Patent No. 5,681,588 (“the ’588 patent"), issued to Knoll… an invention claimed in U.S. Patent No. 5,681,588 (“the '588 patent”), including, for example, research…assigned the patent-in-suit to Abbott Laboratories, lnc. (“Abbott”), which later assigned the patent-in-suit…infringe any valid claims of the patent-in-suit and that the claims of the patent are invalid and DB02;622529…of the patent-in-suit. Dr. Fricke is likely to have relevant information concerning the patent-in-suit External link to document
2007-09-21 115 Order against defendant Par. The patent-in-suit, U.S. Patent No. 5,681,588 (“the ’588 patent”), issued to Knoll Aktiengese_llschaft… ofan invention claimed in U.S. Patent No. 5,681,588 (“the ’588 patent”), including, for example, research…assigned the patent-in-suit to Abbott Laboratories, Inc. (“Abbott”), which later assigned the patent-in-suit…infringe any valid claims of the patent-in-suit and that the claims of the patent are invalid and DBOZ'…invention claimed in the patent-in-suit, the scope of the claims of the patent-in~suit, the meaning of External link to document
2007-12-19 129 Opening Brief in Support for this purpose on September i U.S. Patent No. 5,681,588. DB02:6447376. 1 …prior art U.S. Patent No. 4,797,287 ("the '287 patent" or "Pick patent") assigned…#39;588 patent, (ii) that they believed the '287 patent was material to the patentability of the &…588 patent; (2) that they intentionally failed to disclose the '287 patent to the U.S. Patent and …contends that the '287 patent is material to the patentability of the `588 patent, that the inventors External link to document
2007-12-26 131 Redacted Document phrases “the ’588 patent" or “patent~in suit” means United States Patent No. 5,681,588 entitled “Delayed…540. 'I`he inventors ofU.S. Patent No. 5,681,588 (“the ’588 patent”) and other lndividuais, including…Subject: Certain scientific aspects ofU.S. Patent No. 5,681,588 Case 1:06-cv-00774-JJF Document 131-2 Filed…Subject: Certain scientific aspects of U.S. Patent No. 5,681,588 4. Herbert Mueiler»Peltzer Uferstr.fi 8…Subject: Certain scientific aspects of U.S. Patent No. 5,681,588 5. Claus H. Pich Weriiweg 4 25436 Moon& External link to document
2008-01-11 143 Reply Brief inventors'of the patent-in-suit, U.S. Patent No. 5,681,588 (“the ’588 patent”). ln the Assignment ….S. Patent No. 4,797,287 (“the ’287 patent”), before and/or during prosecution of the ’588 patent Therefore…inventors knew that the ’287 patent was material to the patentability of the ‘ 588 patent and intentionally did…rights under a patent assignment agreement executed by the German inventors of the patent-in-suit to obtain…everything possible to aid [the patent holder] . . . in obtaining and enforcing patents for said invention in all External link to document
2007-03-01 15 Answer to Counterclaim s Counterclaim, Reliant admits that U.S. Patent No. 5,681,588 is assigned to Reliant. 8. Upon information… Reliant admits that it has asserted the ‘5 88 patent against Par, and that Par’s making, use, sale, …release products constitutes infringement of the ‘588 patent claims. Except as expressly admitted herein, all… Reliant admits that it maintains that the ‘588 patent claims are valid. Except as expressly admitted …2006 17 April 2009 1:06-cv-00774-JJF Patent Defendant District Court, D. External link to document
Date Filed Document No. Description Snippet Link To Document

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
QuintilesIMS
McKesson
Chinese Patent Office
Deloitte
Merck
Citi
Daiichi Sankyo
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.